Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI-generated claim regarding increased risk of suicidal thoughts/behaviors in pediatric and young adult patients (≤24 years) with corresponding monitoring and counseling is fully supported by the provided RALDESY boxed warning/warnings language (5.1), pediatric use section (8.4), and patient counseling information (17).
Category Scores
Accurate Statements
Suicidal thoughts and behaviors occur/increase risk in pediatric and young adult patients treated with RALDESY.
Supported by Warnings 5.1 (increased incidence in antidepressant-treated patients age 24 years and younger) and Pediatric Use 8.4 (increased risk in pediatric patients).
Requires monitoring and counseling.
Supported by Warnings 5.1 (monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts/behaviors; counsel family members/caregivers; consider changing regimen/discontinuing if emergent or persistently worse) and Patient Counseling 17 (advise patients/caregivers to look for emergence of suicidality and report to healthcare provider).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response reports on a boxed warning/warnings requirement (monitoring and counseling) that is explicitly described in the provided labeling, without asserting unlabelled or contradictory safety claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement